Several new small‐molecule NLRP3‐specific inhibitors, however, have undergone phase I/II clinical trials such as Inflazome's (purchased by Roche, 2020) brain‐penetrant Inzomelid (IZD174: NCT04086602), Somalix (IZD34: NCT04015076) for treatment of CAPS and IFM Tre's IFM2427 (obtained by Novartis and renamed DFV890; NCT04868968, NCT04382053) tested for CAPS efficacy and recently COVID‐19 pneumonia. Here, NLRP3 is linked to cryopyrin-associated periodic syndrome.